PSIOXUS THERAPEUTICS MOVES INTO NEW FACILITIES ON MILTON PARK TO ACCOMMODATE EXPANSION
New bespoke facilities to enable emerging biotech to further develop novel therapeutics that address cancer and other clinically unmet diseases
Oxford, England: PsiOxus Therapeutics has opened a new state of the art laboratory at Milton Park as part of its expansion plans. The facility has been designed and equipped as a category two laboratory for the handling of live viruses, and will be key to the continued growth of PsiOxus.
Dr John Beadle, Chief Executive Officer at PsiOxus says: "PsiOxus is developing novel viral based therapies and vaccines, with a particular focus upon the treatment of cancer. As our second product will enter clinical trials later this year we needed to expand our organisation and to design a facility to our own specifications. Milton Park offered us an excellent opportunity to create a facility which would support our growth. This prestigious location is already home to many bio-science innovators and MEPC has fitted out our new lab to our exacting standards."
PsiOxus therapeutics employs world-leading scientists and a highly experienced management team to produce novel cancer therapeutics. MT-102 is the most advanced product and is in mid-stage clinical trials for the treatment of cancer cachexia. The second product, ColoAd1, is an oncolytic virus that will enter clinical trials in 2012.
Jo Szegota, Head of Greenlite leasing at Milton Park, adds: "Milton Park has had a major cluster of bio-science companies for many years and across the park our customers include leaders in the pharma, medical and technology industries. We are extremely pleased to be able to welcome PsiOxus to this successful and thriving scientific community. With MEPC's considerable experience in commercial property and Milton Park's specific knowledge of how a modern laboratory needs to function including the creation of controlled clean air environments such as this, we have created a facility which will make PsiOxus feel they belong here with us."
For more press information, please contact Stephen or Zoe at SRF on 01252 850540, or email zoe@communicationmatters.co.uk
Milton Park
Purchased by MEPC in 1985, Milton Park is a thriving commercial environment and one of Europe’s largest business and science parks. Over 200 occupiers employ over 6,500 people to work at Milton Park. Close to the M4 and M40 and with fast rail links from Didcot Parkway to London, Bristol, Oxford and Reading, Milton Park is an ideal location for national and international business.
For more information, please visit: www.mepc.com/miltonpark
For more information about PsiOxus Therapeutics, please contact:
PsiOxus Therapeutics
Dr John Beadle, Chief Executive Officer Tel +44 (0) 7810 770 310
John.beadle@psioxus.com
UK Media Enquiries: Tony Stephenson at Chempetitive Tel +44 (0) 20 3159 4145
tstephenson@chempetitive.com
Or visit www.PsiOxus.com
About PsiOxusTherapeutics, Ltd.
PsiOxus Therapeutics is a development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. The Company’s lead candidate is MT-102, a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and sarcopenia. ColoAd1, an oncolytic virus for the systemic treatment of metastatic cancer, has demonstrated optimal anti-cancer properties in late pre-clinical development. The Company is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.
Tags:
